GI Windows, Inc. Initiates Study on Duodenum to Ileal Diversion for Type 2 Diabetes
A clinical trial is underway to evaluate the efficacy of duodenum to ileal diversion in treating Type 2 Diabetes by monitoring HbA1c changes.
Asset / Drug
Drug and asset intelligence for GI with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.